Mittie K. Doyle

4.8k total citations · 3 hit papers
41 papers, 3.1k citations indexed

About

Mittie K. Doyle is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Mittie K. Doyle has authored 41 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Rheumatology, 19 papers in Hematology and 9 papers in Genetics. Recurrent topics in Mittie K. Doyle's work include Rheumatoid Arthritis Research and Therapies (21 papers), Autoimmune and Inflammatory Disorders Research (17 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Mittie K. Doyle is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (21 papers), Autoimmune and Inflammatory Disorders Research (17 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Mittie K. Doyle collaborates with scholars based in United States, United Kingdom and Canada. Mittie K. Doyle's co-authors include Mahboob U. Rahman, Elizabeth C. Hsia, Arthur Kavanaugh, Proton Rahman, Iain B. McInnes, Christopher T. Ritchlin, L. Puig, Alan M. Mendelsohn, Alice B. Gottlieb and Shu Li and has published in prestigious journals such as The Lancet, Blood and The Journal of Infectious Diseases.

In The Last Decade

Mittie K. Doyle

41 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

2013 606 citations Iain B. McInnes, Arthur Kavanaugh et al. The Lancet profile →
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

2014 508 citations Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases profile →
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mittie K. Doyle United States	24	2.0k	1.4k	1.2k	544	369	41	3.1k
Jeska K de Vries‐Bouwstra Netherlands	29	2.8k 1.4×	568 0.4×	995 0.9×	914 1.7×	656 1.8×	111	3.8k
Joseph Wajdula United States	21	2.7k 1.4×	1.1k 0.8×	1.2k 1.0×	375 0.7×	479 1.3×	35	3.4k
Barbara Finck United States	8	2.7k 1.4×	1.3k 0.9×	1.5k 1.3×	309 0.6×	375 1.0×	17	3.6k
Hanno B. Richards United States	35	3.4k 1.7×	3.5k 2.5×	1.5k 1.3×	358 0.7×	129 0.3×	58	5.0k
S. Kary Germany	19	1.6k 0.8×	876 0.6×	668 0.6×	237 0.4×	223 0.6×	23	2.2k
Majed Khraishi Canada	22	1.5k 0.8×	1.2k 0.9×	725 0.6×	186 0.3×	125 0.3×	65	2.2k
Gurtej S. Cheema United States	24	1.3k 0.7×	1.2k 0.8×	283 0.2×	489 0.9×	172 0.5×	26	2.9k
Luminita Pricop United States	30	2.7k 1.4×	3.5k 2.5×	1.6k 1.4×	241 0.4×	109 0.3×	115	4.7k
Saeed Fatenejad United States	23	2.9k 1.5×	1.2k 0.8×	1.2k 1.0×	456 0.8×	479 1.3×	37	3.8k
Shephard Mpofu United States	24	2.9k 1.5×	2.9k 2.1×	1.8k 1.5×	239 0.4×	87 0.2×	68	4.1k

Countries citing papers authored by Mittie K. Doyle

Since Specialization

Citations

This map shows the geographic impact of Mittie K. Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mittie K. Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mittie K. Doyle more than expected).

Fields of papers citing papers by Mittie K. Doyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mittie K. Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mittie K. Doyle. The network helps show where Mittie K. Doyle may publish in the future.

Co-authorship network of co-authors of Mittie K. Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of Mittie K. Doyle. A scholar is included among the top collaborators of Mittie K. Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mittie K. Doyle. Mittie K. Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ritchlin, Christopher T., Proton Rahman, Arthur Kavanaugh, et al.. (2014). Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases. 73(6). 990–999. 508 indexed citations breakdown →

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2014). 85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. Lara D. Veeken. 53(suppl_1). i87–i88. 2 indexed citations

Fürst, Daniel E., Jonathan Kay, Mary Chester Wasko, et al.. (2013). The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Lara D. Veeken. 52(10). 1845–1855. 26 indexed citations

Saketkoo, Lesley Ann, Jeanette H. Magnus, & Mittie K. Doyle. (2013). The Primary Care Physician in the Early Diagnosis of Systemic Sclerosis: The Cornerstone of Recognition and Hope. The American Journal of the Medical Sciences. 347(1). 54–63. 16 indexed citations

McInnes, Iain B., Arthur Kavanaugh, Alice B. Gottlieb, et al.. (2013). Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. The Lancet. 382(9894). 780–789. 606 indexed citations breakdown →

Doyle, Mittie K., Mahboob U. Rahman, Bart Frederick, et al.. (2013). Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Lara D. Veeken. 52(7). 1214–1219. 37 indexed citations

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2013). THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. Annals of the Rheumatic Diseases. 72. A232–A232. 2 indexed citations

Hsia, Elizabeth C., Neil W. Schluger, John J. Cush, et al.. (2012). Interferon‐γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti–tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis & Rheumatism. 64(7). 2068–2077. 62 indexed citations

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2012). Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Annals of the Rheumatic Diseases. 71(10). 1671–1679. 49 indexed citations

10.

Rahman, Mahboob U., Jacqueline Buchanan, Mittie K. Doyle, et al.. (2011). Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Annals of the Rheumatic Diseases. 70(9). 1631–1640. 61 indexed citations

11.

Wordsworth, P, Mittie K. Doyle, J. Smolen, et al.. (2010). GOLIMUMAB SIGNIFICANTLY IMPROVES PHYSICAL FUNCTION AND FATIGUE IN RA PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF AGENTS: RESULTS FROM THE GO-AFTER STUDY. Lara D. Veeken. 49. 3 indexed citations

12.

Matucci‐Cerinic, Marco, CP Denton, D.E. Furst, et al.. (2010). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 70(1). 32–38. 322 indexed citations

13.

Wordsworth, P, Josef S Smolen, Mittie K. Doyle, et al.. (2009). GOLIMUMAB, A HUMAN TNF-ALPHA mu ONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS PREVIOUSLY TREATED WITH ANTI-TNF-ALPHA AGENTS (GO-AFTER STUDY). Lara D. Veeken. 48. 1 indexed citations

14.

Braun, Jürgen, Désirée van der Heijde, Mittie K. Doyle, et al.. (2009). Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care & Research. 61(8). 1032–1036. 27 indexed citations

15.

Smolen, Josef S, Jonathan Kay, Mittie K. Doyle, et al.. (2009). Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet. 374(9685). 210–221. 423 indexed citations breakdown →

16.

Doyle, Mittie K., Mahboob U. Rahman, Chenglong Han, et al.. (2008). Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures—A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials. Seminars in Arthritis and Rheumatism. 39(2). 123–131. 48 indexed citations

17.

Doyle, Mittie K., Ruth Berggren, & Jeanette H. Magnus. (2006). Interferon-Induced Sarcoidosis. JCR Journal of Clinical Rheumatology. 12(5). 241–248. 39 indexed citations

18.

Doyle, Mittie K., et al.. (2003). Minimally Displaced Colles’ Fractures: A Prospective Randomized Trial of Treatment With a Wrist Splint or a Plaster Cast. Journal of Hand Surgery (European Volume). 28(1). 50–53. 30 indexed citations

19.

Doyle, Mittie K., Sam R. Telford, Lisa G. Criscione, et al.. (1998). Cytokines in Murine Lyme Carditis: Th1 Cytokine Expression Follows Expression of Proinflammatory Cytokines in a Susceptible Mouse Strain. The Journal of Infectious Diseases. 177(1). 242–246. 32 indexed citations

20.

Merkel, Peter A., et al.. (1997). Heterotopic ossification in the setting of neuromuscular blockade. Arthritis & Rheumatism. 40(9). 1619–1627. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact